Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/25/2026

1. COST
2. AKAM
3. SPY
4. ZS
5. ULS

6. META
7. CRL
8. PRME
9. DRI
10. NTRBW

Get Alerts ZNTL Hot Sheet

Price: $2.75 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

NEW YORK and SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in two upcoming virtual investor conferences.

Presentation Details:

Event: Morgan Stanley 18th Annual Global Healthcare Conference Date: Thursday, September 17, 2020Time: 8:45 a.m. ET

Event: Cantor Fitzgerald Virtual Global Healthcare ConferenceDate: Thursday, September 17, 2020Time: 10:00 a.m. ET

Live webcasts from the Morgan Stanley and Cantor fireside chats will be accessible through the Investors section of the Company’s website at www.zentalis.com. Following the events, archived webcasts will be available on the Zentalis website.

About Zentalis

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor. Zentalis has operations in both New York and San Diego.

For more information, please visit www.zentalis.com. Follow Zentalis on Twitter at @ZentalisP and on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.

Investor Contact:Thomas HoffmannSolebury Trout1.646.378.2931[email protected]

Media Contact:Julia DeutschSolebury Trout1.646.378.2967[email protected]